Theravance Biopharma, Inc. (TBPH) - Stock Analysis
Last updated: Jan 14, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Theravance Biopharma benefits from record sales growth, upcoming Phase 3 CYPRESS data expected Q1 2026 as a key catalyst, positive technical momentum (+27% last month), and strong sector tailwinds, supporting near-term upside despite ongoing losses and high valuation.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠High cash balance ⢠Negative operating history ⢠Elevated valuation TBPH's liquidity and leverage improved materially by 2025-09-30, but sustained operating losses, negative free cash flow and large retained deficits undermine that strength and the stock appears richly valued.
Price Behavior
Key Price Behavior Insights: ⢠Steady upward trend ⢠Near-term support ⢠Profit-taking risk Support Level: $18.00â$18.50 Resistance Level: $19.00 (recent high $20.33) Over the last month TBPH has shown a steady climb from about $18.16 to $20.33, holding $18.00â$18.50 as near-term support after clearing $19.00 and approaching $20.30 where profit-taking could appear.
Sentiment & News
Key News Insights: ⢠Analyst 42% upside ⢠Assenagon stake surge ⢠Momentum ratings rise Investor and analyst momentum for Theravance Biopharma (TBPH) strengthened into late 2025âearly 2026, driven by bullish Zacks/momentum calls, a ~42% analyst upside projection, and a >1,600% institutional stake increase.
AI Summary
TBPH has shifted into a hybrid commercialâandâclinical story where growing YUPELRI revenue and ~$75M of nearâterm partner milestones materially deârisk the runway and justify a floor, but the stock remains binaryâsize positions for a single Phaseâ3 ampreloxetine readout that can sharply reârate or reverse the thesis if negative or delayed.
Description
Theravance Biopharma is a biopharmaceutical company that researches, develops and commercializes respiratory medicines across the United States, Europe and Asia, with YUPELRI sold as a nebulized, once-daily therapy for COPD. Its clinical pipeline includes inhaled and gut-targeted small moleculesânotably several JAK inhibitors and other candidates addressing pulmonary and gastrointestinal disordersâalongside later-stage programs for autonomic and motility conditions. The company maintains licensing and collaboration agreements with major pharmaceutical partners and is incorporated in 2013 with headquarters in George Town, Cayman Islands.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Dec 5 | Dec 12 | TBPH | Theravance Biopharma, Inc. | Theravance Biopharma benefits from record sales growth, upcoming Phase 3 CYPRESS data expected Q1 2026 as a key catalyst, positive technical momentum (+27% last month), and strong sector tailwinds, supporting near-term upside despite ongoing losses and high valuation. | Closed | -2.1% |